[Transplacental passage of the antiviral agent, bonafton]. / Issledovanie transplatsentarnogo perekhoda protivovirusnogo preparata bonaftona.

The ability of 14C-bonafton to penetrate the placental bar was studied in female Wistar rats. The drug was shown to penetrate through the placenta in insignificant amounts. The maximal quantities of the drug which entered the fetuses proper during the last third of pregnancy do not exceed 0.55% of 14C-bonafton content in the mother's blood. It was revealed that bonafton transplacental penetration is barred by fetal envelopes.

[Pharmacokinetics of the antiviral preparation, bonafton]. / Farmakokinetika protivovirusnogo preparata bonaftona.

The parameters of bonafton pharmacokinetics (absorption, distribution, excretion) have been studied in male Wistar rats at single enteral and intraperitoneal administration. With these routes of administration daily resorption amounts to 26 and 100%, respectively. Regardless administration routes 14C-bonafton distributes in a similar way in the internal organs and tissues and is excreted through the kidneys and gastrointestinal tract, the latter way of excretion being predominant. T1 = 0.25 day (24%) and T2 = 1.8 day. A two-chamber model of the drug metabolism is suggested. This model allows a calculation of bonafton and its metabolites accumulation at repeated administration of the drug to the body.